BACKGROUND: Diminished serum arylesterase activity, catalyzed by the high-density lipoprotein-associated paraoxonase-1, is associated with heightened systemic oxidative stress and atherosclerosis risk. In the present study, we sought to determine the prognostic role of serum arylesterase activity in subjects with systolic heart failure, particularly in relation to established cardiac biomarkers. METHODS AND RESULTS: We measured serum arylesterase activity in 760 subjects with impaired left ventricular systolic function (left ventricular ejection fraction <50%), and prospectively followed major adverse cardiac events (including death, nonfatal myocardial infarction, and stroke) for 3 years. In our study cohort (mean age, 64±11 years; 74% men; median left ventricular ejection fraction, 35%; median creatinine clearance, 96 mg/dL), mean serum arylesterase activity (98±25 μmol/L/min/mL) was lower compared with that in healthy control subjects (mean, 115±26 μmol/L/min/mL, P<0.01) but higher compared with advanced decompensated heart failure subjects (mean, 69±22 μmol/L/min/mL, P<0.01). Within our cohort, there was modest correlation between serum arylesterase activity and high-density lipoprotein cholesterol (r=0.33, P<0.01) as well as B-type natriuretic peptide (r=-0.23, P<0.01). Lower serum arylesterase activity was a strong predictor of poorer outcomes (hazard ratio, 2.94; 95% confidence interval, 1.54, 5.62; P<0.001). After adjusting for traditional risk factors, medication use, B-type natriuretic peptide, and creatinine clearance, lower serum arylesterase still conferred an increased risk of major adverse cardiac events at 3 years (hazard ratio, 2.69; 95% confidence interval, 1.37 to 5.28; P=0.004). CONCLUSIONS: In patients with systolic heart failure, decreased serum arylesterase activity, a measure of diminished antioxidant properties of high-density lipoprotein, predicts higher risk of incident long-term adverse cardiac event independent of established clinical and biochemical risk factors.
BACKGROUND: Diminished serum arylesterase activity, catalyzed by the high-density lipoprotein-associated paraoxonase-1, is associated with heightened systemic oxidative stress and atherosclerosis risk. In the present study, we sought to determine the prognostic role of serum arylesterase activity in subjects with systolic heart failure, particularly in relation to established cardiac biomarkers. METHODS AND RESULTS: We measured serum arylesterase activity in 760 subjects with impaired left ventricular systolic function (left ventricular ejection fraction <50%), and prospectively followed major adverse cardiac events (including death, nonfatal myocardial infarction, and stroke) for 3 years. In our study cohort (mean age, 64±11 years; 74% men; median left ventricular ejection fraction, 35%; median creatinine clearance, 96 mg/dL), mean serum arylesterase activity (98±25 μmol/L/min/mL) was lower compared with that in healthy control subjects (mean, 115±26 μmol/L/min/mL, P<0.01) but higher compared with advanced decompensated heart failure subjects (mean, 69±22 μmol/L/min/mL, P<0.01). Within our cohort, there was modest correlation between serum arylesterase activity and high-density lipoprotein cholesterol (r=0.33, P<0.01) as well as B-type natriuretic peptide (r=-0.23, P<0.01). Lower serum arylesterase activity was a strong predictor of poorer outcomes (hazard ratio, 2.94; 95% confidence interval, 1.54, 5.62; P<0.001). After adjusting for traditional risk factors, medication use, B-type natriuretic peptide, and creatinine clearance, lower serum arylesterase still conferred an increased risk of major adverse cardiac events at 3 years (hazard ratio, 2.69; 95% confidence interval, 1.37 to 5.28; P=0.004). CONCLUSIONS: In patients with systolic heart failure, decreased serum arylesterase activity, a measure of diminished antioxidant properties of high-density lipoprotein, predicts higher risk of incident long-term adverse cardiac event independent of established clinical and biochemical risk factors.
Authors: Sophie Van Linthout; Frank Spillmann; Alexander Riad; Christiane Trimpert; Joke Lievens; Marco Meloni; Felicitas Escher; Elena Filenberg; Okan Demir; Jun Li; Mehdi Shakibaei; Ingolf Schimke; Alexander Staudt; Stephan B Felix; Heinz-Peter Schultheiss; Bart De Geest; Carsten Tschöpe Journal: Circulation Date: 2008-03-10 Impact factor: 29.690
Authors: Corstian A den Uil; E Klijn; W K Lagrand; J J Brugts; C Ince; P E Spronk; M L Simoons Journal: Prog Cardiovasc Dis Date: 2008 Sep-Oct Impact factor: 8.194
Authors: Hans Wedel; John J V McMurray; Magnus Lindberg; John Wikstrand; John G F Cleland; Jan H Cornel; Peter Dunselman; Ake Hjalmarson; John Kjekshus; Michel Komajda; Timo Kuusi; Johan Vanhaecke; Finn Waagstein Journal: Eur J Heart Fail Date: 2009-01-24 Impact factor: 15.534
Authors: Ying Huang; Zhiping Wu; Meliana Riwanto; Shengqiang Gao; Bruce S Levison; Xiaodong Gu; Xiaoming Fu; Matthew A Wagner; Christian Besler; Gary Gerstenecker; Renliang Zhang; Xin-Min Li; Anthony J DiDonato; Valentin Gogonea; W H Wilson Tang; Jonathan D Smith; Edward F Plow; Paul L Fox; Diana M Shih; Aldons J Lusis; Edward A Fisher; Joseph A DiDonato; Ulf Landmesser; Stanley L Hazen Journal: J Clin Invest Date: 2013-08-01 Impact factor: 14.808
Authors: Muhammad Hammadah; Marie-Luise Brennan; Yuping Wu; Stanley L Hazen; W H Wilson Tang Journal: Am J Cardiol Date: 2016-01-28 Impact factor: 2.778
Authors: Hyo Sang Jang; Xiaodong Gu; Richard B Cooley; Joseph J Porter; Rachel L Henson; Taylor Willi; Joseph A DiDonato; Stanley L Hazen; Ryan A Mehl Journal: ACS Chem Biol Date: 2020-02-10 Impact factor: 5.100
Authors: W H Wilson Tang; Zeneng Wang; Yiying Fan; Bruce Levison; Jennie E Hazen; Lillian M Donahue; Yuping Wu; Stanley L Hazen Journal: J Am Coll Cardiol Date: 2014-10-27 Impact factor: 24.094
Authors: Wei Li; David Kennedy; Zhili Shao; Xi Wang; Andre Klaassen Kamdar; Malory Weber; Kayla Mislick; Kathryn Kiefer; Rommel Morales; Brendan Agatisa-Boyle; Diana M Shih; Srinivasa T Reddy; Christine S Moravec; W H Wilson Tang Journal: Free Radic Biol Med Date: 2018-05-02 Impact factor: 7.376
Authors: W H Wilson Tang; Jaana Hartiala; Yiying Fan; Yuping Wu; Alexandre F R Stewart; Jeanette Erdmann; Sekar Kathiresan; Robert Roberts; Ruth McPherson; Hooman Allayee; Stanley L Hazen Journal: Arterioscler Thromb Vasc Biol Date: 2012-09-13 Impact factor: 8.311